
Everyone Deserves a Shot at the American Dream: Sinus Rhythm
The bottom line: Ablation alone was better than the combination of the two noninvasive approaches in tandem at keeping these patients free from AF after a year.
But some electrophysiologists say the trial results should not mean clinicians should default to one approach vs the other but rather that they help validate a combination of ablation plus lifestyle modification to optimize outcomes for patients with AF.
A 'Hybrid Approach'
The PRAGUE-25 trial randomized 212 patients with AF to CA alone or lifestyle modification plus medication to control their arrhythmias. The primary endpoint was freedom from AF at 12 months, achieved by 73% of patients in the ablation-only group and 34.6% of those who had lifestyle modification plus medication therapy. At 24 months, that outcome had shifted to 55.6% of the former and 24.7% of the latter.
'I personally think that ultimately what's important is a hybrid approach,' Sana Al-Khatib, MD, MHS, an electrophysiologist at Duke University in Durham, North Carolina, told Medscape Medical News . 'You, of course, control the patient's risk factors and also consider them for catheter ablation because we know it's superior for rhythm control vs medication, but for the results of the catheter ablation to be optimized, and in my view to ensure the durability of the effect of catheter ablation, I think controlling risk factors like lifestyle modification is very important.'
Kenneth Ellenbogen, MD
'The results of trial suggest to no surprise that catheter ablation is a very, very powerful treatment, far more effective than risk factor modification,' said Kenneth Ellenbogen, MD, former president of the Heart Rhythm Society and an electrophysiologist at the Pauley Heart Center, Virginia Commonwealth University, in Richmond, Virginia.
Although Ellenbogen said he considers PRAGUE-25 'an important trial, the take-home message for cardiologists should be that everyone can have risk factor modification — and catheter ablation. The patients who do both are going to do better than the patients who do one or the other,' he said.
A study comparing patients who had ablation plus risk factor modification compared with ablation alone 'would've been interesting,' he added.
The Importance of Sinus Rhythm
The PRAGUE 25 researchers based their premise on the 2015 LEGACY trial, a study that followed patients with overweight on weight management over 5 years that found an association between sustained weight loss and a sharp reduction in AF burden and maintenance of sinus rhythm (SR).
The importance of maintaining SR received an endorsement last year with an analysis of patients in the CABANA trial (CA vs Antiarrhythmic Drug Therapy for AF). The analysis of 883 patients with AF found those in SR were 43% less likely to meet the primary endpoint — death, disabling stroke, serious bleeding, or cardiac arrest — than those who did not have SR, regardless of whether they had received ablation or were taking therapy. Patients in normal rhythm had a 41% lower risk for all-cause death.
Eric Prystowsky, MD
The evidence supporting the benefit of prioritizing SR over rate control has evolved steadily over the past three decades, said Eric Prystowsky, MD, director of Cardiac Arrhythmia Service at Ascension St. Vincent Hospital in Indianapolis, and a consulting professor at Duke University Medical Center, Durham, North Carolina. Rate control became the preferred strategy after the AFFIRM trial in 2002 and found rhythm control offered no survival advantage compared with rate control, with the latter having potential advantages, such as fewer adverse drug reactions and lower risk for death.
Within a few years, more data tipped the scales in favor of rhythm control. In 2009 the CAFÉ-II study, although small (61 patients), found restoring SR in patients with AF and heart failure improved quality of life and left ventricular function better than rate control. By 2018, Prystowsky was calling SR 'a bridge to the future' in patients with AF.
'The bridge to the future concept is to understand that, if I as a physician don't do anything, you'll be in Afib [AF] for the rest of your life and that can have debilitating consequences for the future,' Prystowsky told Medscape Medical News .
That same year, the CASTLE-AF study concluded ablation was more effective at maintaining SR and reducing the risk of worsening heart failure than medical therapy.
In a 2022 commentary in the journal Circulation , Prystowsky asked if the debate of rate vs rhythm control had been settled. Clinicians should discuss the benefits of SR with patients when AF is first diagnosed, he wrote, with rhythm control the preferred option in patients with heart failure and those aged 70 years and younger.
Sana Al-Khatib, MD, MHS
In an editorial last year in Circulation: Arrhythmia and Electrophysiology, Al-Khatib pointed out guidance from the American Heart Association/American College of Cardiology/Heart Rhythm Society between 2014 and 2019 recommended rhythm control in patients who had symptoms despite adequate rate control, making rhythm control subordinate to rate control.
In 2023, the three groups updated their statement to recommend early rhythm control and focusing on maintaining SR and minimizing the burden of AF burden for management of the condition. Maintaining SR 'can be useful' to reduce hospitalization, stroke, death and AF progression in patients who had been diagnosed with AF in the past year, the groups stated. The tide had turned in favor of SR compared with rate control.
'In the past it was difficult to keep everyone in sinus rhythm, but we have newer methods now that are much more effective and it's not quite the struggle,' Prystowsky said. 'But it does require patience. It requires you to know a lot about antiarrhythmic drugs because ablation is not the only option. And it requires that you know what techniques are best for which patient. It's not an easy process.'
'Atrial fibrillation,' he added, 'is easy to diagnose and frankly hard to treat.'
Getting to Sinus
The first step, experts said, is convincing patients that rhythm control is essential.
'It's important to keep this in mind when we see these patients to counsel them to make sure that they understand that unless you do something about the atrial fibrillation to try to keep them in sinus rhythm, in many patients atrial fibrillation gets worse over time,' Al-Khatib said.
Ablation isn't for everyone with AF, Prystowsky said. 'Patients in their mid-to-late 80s that are comfortable in Afib may not be appropriate,' he said. 'It's not that everybody needs it, but the discussion and consideration of sinus rhythm is appropriate for every patient.'
Lifestyle modification is 'very hard, though,' he said. 'Without an organized program for weight loss, you just can't get people to take off 10% of their body weight and keep it off.'
The widening availability of GLP-1 agonists for weight loss could drastically alter how cardiologists and electrophysiologists approach AF in patients who are obese and overweight, Prystowsky said. 'It's not just about losing weight. It might affect the metabolic activity of the pericardial fat and reduce Afib,' he said.
One combined approach could involve CA with antiarrhythmic medication afterward, Prystowsky said. 'It's not uncommon to do an ablation and get three quarters of the job done, and the patient is still having episodes,' he said. 'Then you add a drug like dofetilide, and they have nothing. They can go for years feeling great or not need a second ablation.'
But, Ellenbogen said, 'very, very, very few' patients would not be candidates for ablation.
'Antiarrhythmic drugs alone are fine, but they're only a short-term solution,' he said. 'In most people who take antiarrhythmic drugs, over time there's progression of disease. Typically, in 2 years 50% who take antiarrhythmic drugs are back in Afib.'
When discussing AF with patients, clinicians should focus on the severity and progression of symptoms, not the mere presence of AF, Al-Khatib said. 'If the patient starts with rare episodes of atrial fibrillation, I don't think anyone would do a procedure, but you have to keep an eye on the progression of the Afib,' Al-Khatib said. 'As it gets more frequent and the episodes start lasting longer, then it is important to intervene with rhythm controlling strategies earlier.'
In the end, experts said, the best strategy to achieve SR is the one that works.
'The punchline is that for maintenance of sinus rhythm, catheter ablation is the most effective method and more effective than risk factor modification,' Ellenbogen said. 'But it's a false narrative here. We want all our patients to do both, and both together is very, very profoundly effective.'
Ellenbogen disclosed honorarium from Medtronic. Al-Khatib and Prystowsky reported no relevant financial relationships.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
8 hours ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.


Bloomberg
9 hours ago
- Bloomberg
Roche to Test Whether New Drug Can Prevent Alzheimer's Disease
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmaking. The new late-stage study will focus on people who are at risk of cognitive decline, Roche said in a statement late Sunday. The goal would be to slow down the emergence of symptoms, or prevent them entirely.